View all of Sowmya Viswanathan’s publications in PubMed, Scopus and ORCID.

BookMesenchymal Stromal Cells, 2017

Book chaptersOsteoarthritis, 2015; Mesenchymal Stromal Cells, 2013; New Perspectives in Regeneration, 2013


Banh L, Cheung KK, Chan MWY, Young EWK, Viswanathan S. (2022). Advances in Organ-on-a-Chip Systems for Modelling Joint Tissue and Osteoarthritic Diseases. Osteoarthritis and Cartilage. 20 April 2022

Sartore, L*, Pasini, C, Pandini, S, Dey, K, Ferrari, M, Taboni, S, Chan, H HL, Townson, J, Viswanathan, S, Mathews, S, Gilbert, R W, Irish, J C, Re, F, Nicolai, P, Russo, D. Hybrid core-shell polymer scaffold for bone tissue regeneration. International Journal of Molecular Sciences. 2022 April 20

Viswanathan, S, Moreyra, P A, Berenbaum, F, Danda, D, Grotsch, B, Stones S R. How the COVID-19 pandemic has affected rheumatology research. Nature Reviews Rheumatology. 2022 Jan 11

Chan, MWY, Gómez-Aristizábal, A, Mahomed, N, Gandhi, R, Viswanathan, S. A tool for evaluating novel osteoarthritis therapies using multivariate analyses of human cartilage-synovium explant co-culture. Osteoarthritis and Cartilage. 2021 Sep 14; S1063-4584(21)00910-9 

Viswanathan S, Ciccocioppo R, Galipeau J, et al. Consensus ICCBBA-ISCT statement on standard nomenclature abbreviations for the tissue of origin of Mesenchymal Stromal Cells. Cytotherapy. 2021; S1465-3249(21)00644-7 

Lin-Gibson, S, Lin, NJ, Jackson, S, et al. Standards efforts and landscape for rapid microbial testing methodologies in regenerative medicine. Cytotherapy. 2021;S1465-3249(20)30793-3.

Galipeau J, Krampera M, Leblanc K, et al. Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predispositionCytotherapy. 2021; S1465-3249(20)30960-9. doi:10.1016/j.jcyt.2020.11.007

Abji F, Rasti M, Gómez-Aristizábal A, et al. Proteinase-mediated Macrophage Signalling in Psoriatic Arthritis. Front Immunol. 2021;11:629726. doi:10.3389/fimmu.2020.629726

Khoury M, Rocco PRM, Phinney DG, et al. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. Cytotherapy. 2020;22(11):602-605. doi:10.1016/j.jcyt.2020.04.089

Rockel JS, Rabani R, Viswanathan S. Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases. Semin Cell Dev Biol. 2020;101:87‐103. doi:10.1016/j.semcdb.2019.10.014

Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019‐1024. doi:10.1016/j.jcyt.2019.08.002

Chisholm J, Ruff C, Viswanathan S. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. 2019;21(7):686‐698. doi:10.1016/j.jcyt.2019.03.005

Chahal J, Gómez-Aristizábal A, Shestopaloff K, et al. Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation. Stem Cells Transl Med. 2019;8(8):746‐757. doi:10.1002/sctm.18-0183 This article was ranked #1 most-read paper of 2019 by Stem Cells Translational Medicine.

Bubela T, Boch R, Viswanathan S. Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada. Front Med (Lausanne). 2019;6:58. doi:10.3389/fmed.2019.00058

Hamilton AM, Cheung WY, Gómez-Aristizábal A, et al. Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action. PLoS One. 2019;14(12):e0214107. doi:10.1371/journal.pone.0214107

Robb KP, Fitzgerald JC, Barry F, Viswanathan S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy. 2019;21(3):289‐306. doi:10.1016/j.jcyt.2018.10.014

Chan MWY, Viswanathan S. Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases. Cytotherapy. 2019;21(4):393‐415. doi:10.1016/j.jcyt.2019.02.002

Gómez-Aristizábal A, Gandhi R, Mahomed NN, Marshall KW, Viswanathan S. Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study. Arthritis Res Ther. 2019;21(1):26. doi:10.1186/s13075-018-1798-2

Fink C, Gaudet JM, Fox MS, et al. 19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting. Sci Rep. 2018;8(1):590. doi:10.1038/s41598-017-19031-0

Chisholm J, von Tigerstrom B, Bedford P, Fradette J, Viswanathan S. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada. Cytotherapy. 2017;19(12):1400‐1411. doi:10.1016/j.jcyt.2017.08.015

Williams BA, Law AD, Routy B, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8(51):89256‐89268. doi:10.18632/oncotarget.19204

Yannarelli G, Pacienza N, Montanari S, Santa-Cruz D, Viswanathan S, Keating A. OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells. PLoS One. 2017;12(12):e0189131. doi:10.1371/journal.pone.0189131

Chisholm J, Bhatt S, Chaboureau A, Viswanathan S. Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval. Cytotherapy. 2017;19(12):1529‐1536. doi:10.1016/j.jcyt.2017.09.004

Gómez-Aristizábal A, Sharma A, Bakooshli MA, et al. Stage-specific differences in secretory profile of mesenchymal stromal cells (MSCs) subjected to early- vs late-stage OA synovial fluid. Osteoarthritis Cartilage. 2017;25(5):737‐741. doi:10.1016/j.joca.2016.11.010

Rashedi I, Gómez-Aristizábal A, Wang XH, Viswanathan S, Keating A. TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell-Mediated Treg Induction via Notch Signaling. Stem Cells. 2017;35(1):265‐275. doi:10.1002/stem.2485

Juneja SC, Viswanathan S, Ganguly M, Veillette C. A Simplified Method for the Aspiration of Bone Marrow from Patients Undergoing Hip and Knee Joint Replacement for Isolating Mesenchymal Stem Cells and In Vitro Chondrogenesis. Bone Marrow Res. 2016;2016:3152065.

Gómez-Aristizábal A, Kim KP, Viswanathan S. A Systematic Study of the Effect of Different Molecular Weights of Hyaluronic Acid on Mesenchymal Stromal Cell-Mediated Immunomodulation. PLoS One. 2016;11(1):e0147868. doi:10.1371/journal.pone.0147868

Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151‐159. doi:10.1016/j.jcyt.2015.11.008

Montanari S, Dayan V, Yannarelli G, et al. Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model. J Heart Lung Transplant. 2015;34(11):1481‐1488. doi:10.1016/j.healun.2015.05.008

Bubela T, McCabe C, Archibald P, et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen Med. 2015;10(7):897‐911. doi:10.2217/rme.15.51

Viswanathan S, Bubela T. Current practices and reform proposals for the regulation of advanced medicinal products in Canada. Regen Med. 2015;10(5):647‐663. doi:10.2217/rme.15.28